![Jared Gollob](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jared Gollob
No open positions remaining
Net worth: 8 M $ as of 30/06/2026
Profile
Jared Gollob worked at Duke University from 2002 to 2007 as Director of the Biologic Therapy Program.
From 2007 to 2018, worked at Alnylam Pharmaceuticals, Inc., serving as Global VP of Medical Affairs and Clinical Development from 2012 to 2018.
From 2018 to 2026, worked at Kymera Therapeutics, Inc. as Chief Medical Officer.
Former jobs include Director-Biologic Therapy Program at Duke University and Global VP-Medical Affairs & Clinical Development at Alnylam Pharmaceuticals, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/03/2026 | 71,359 ( 0.09% ) | 8 M $ | 30/06/2026 |
Former positions of Jared Gollob
| Companies | Position | End |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 27/07/2026 |
| ALNYLAM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/08/2018 |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/09/2007 |
Training of Jared Gollob
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
92
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
- Stock Market
- Insiders
- Jared Gollob
